Publicaciones científicas

Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study

Delgado-Alvarado M (1), Dacosta-Aguayo R (1,2), Navalpotro-Gómez I 1,2, Gago B (1,2), Gorostidi A (1,2,3), Jiménez-Urbieta H (1,2), Quiroga-Varela A (1,2,4), Ruiz-Martínez J (1,2,5), Bergareche A (1,2,5), Rodríguez-Oroz MC (1,2,4,5,6,7).

(1) Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.
(2) Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
(3) Genomics Platform, Biodonostia Research Institute, San Sebastián, Spain.
(4) Clinica Universidad de Navarra, Center for Applied Medical Research (CIMA)-Universidad de Navarra, Pamplona, Spain.
(5) Movement Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain.
(6) Ikerbasque (Basque Foundation for Science), Bilbao, Spain.
(7) Basque Center on Cognition Brain and Language (BCBL), San Sebastián, Spain.

Revista: Movement Disorders

Fecha: 13-nov-2018

Neurología

BACKGROUND:

There is a need for biomarkers of dementia in PD.

OBJECTIVES:

To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term.

METHODS:

The Parkinson's Progression Markers Initiative database was used as an exploratory cohort, and a center-based cohort was used as a replication cohort. Amyloid ß1-42, total tau, threonine-181 phosphorylated tau, and α-synuclein in the CSF and the ratios of these proteins were assessed.

RESULTS:

In the Parkinson's Progression Markers Initiative cohort (n = 281), the total tau/amyloid ß1-42, total tau/α-synuclein, total tau/amyloid ß1-42+α-synuclein, and amyloid ß1-42/total tau ratios were associated with a risk of progression to dementia over a 3-year follow-up. In the replication cohort (n = 40), the total tau/α-synuclein and total tau/amyloid ß1-42+α-synuclein ratios were associated with progression to dementia over a 41-month follow-up.

CONCLUSION:

Ratios of the main proteins found in PD patient brain inclusions that can be measured in the CSF appear to have value as short- to mid-term predictors of dementia.

CITA DEL ARTÍCULO  Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27518.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra